You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Drug Price Trends for DEXTROMETHORPHAN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DEXTROMETHORPHAN

Average Pharmacy Cost for DEXTROMETHORPHAN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
DEXTROMETHORPHAN ER 30 MG/5 ML 45802-0433-21 0.06347 ML 2025-05-21
DEXTROMETHORPHAN 15 MG SOFTGEL 00536-1334-34 0.10942 EACH 2025-05-21
DEXTROMETHORPHAN ER 30 MG/5 ML 45802-0433-21 0.06385 ML 2025-04-23
DEXTROMETHORPHAN 15 MG SOFTGEL 00536-1334-34 0.11168 EACH 2025-04-23
DEXTROMETHORPHAN ER 30 MG/5 ML 45802-0433-21 0.06493 ML 2025-03-19
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for DEXTROMETHORPHAN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
DEXTROMETHORPHAN 20MG/GUAIFENESIN 400MG TAB Richmond Pharmaceuticals Inc. 54738-0985-30 30 2.69 0.08967 EACH 2024-02-15 - 2029-02-14 FSS
DEXTROMETHORPHAN 20MG/GUAIFENESIN 400MG TAB Richmond Pharmaceuticals Inc. 54738-0985-60 60 3.90 0.06500 EACH 2024-02-15 - 2029-02-14 FSS
DEXTROMETHORPHAN 15MG/PROMETHAZINE 6.25MG/5ML Golden State Medical Supply, Inc. 70436-0155-41 473ML 8.70 0.01839 ML 2023-06-16 - 2028-06-14 FSS
DEXTROMETHORPHAN 15MG/PROMETHAZINE 6.25MG/5ML Golden State Medical Supply, Inc. 70436-0155-42 473ML 34.82 0.07362 ML 2023-06-16 - 2028-06-14 FSS
DELSYM 12 HOUR (GRAPE) RB Health (US) LLC 63824-0171-65 148ML 8.60 0.05811 ML 2022-06-15 - 2027-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Dextromethorphan Market Analysis and Price Projections

Market Overview

Dextromethorphan, a widely used cough suppressant, is experiencing significant growth in the global market. The market size was valued at USD 413.78 million in 2024 and is projected to exceed USD 724.23 million by 2037, with a Compound Annual Growth Rate (CAGR) of over 4.4% during the forecast period of 2025-2037[1].

Market Drivers

Several factors are driving the growth of the dextromethorphan market:

Rising Prevalence of Respiratory Conditions

The increasing cases of severe cough, flu, bronchitis, and other respiratory problems due to allergies, pollution, and other factors are major drivers. For instance, cough is among the most common medical complaints globally, accounting for nearly 30 million clinical visits annually[1].

Growing Consumer Awareness and Self-Medication

Increased access to healthcare information has led to higher self-medication practices. Consumers are more likely to seek relief from cough symptoms using over-the-counter medications like dextromethorphan, contributing to market growth[2].

Investment in Healthcare Facilities

The expansion of healthcare facilities, particularly in regions like North America and Asia-Pacific, is also boosting the market. The rising number of hospitals and the trust associated with hospital settings are significant factors[1].

Launch of New Formulations

The introduction of new dextromethorphan-based drugs, such as Sun Pharmaceutical's Chericof 12 in India, which provides relief for up to 12 hours using Polistirex technology, is expected to further drive market expansion[3][5].

Market Segmentation

By Product Type

The market is segmented into over-the-counter (OTC) and prescription drugs. OTC products dominate the market due to high demand and ease of access[2].

By Dosage Form

The market is segmented into syrups, tablets, and other dosage forms. Syrups are particularly popular due to their ease of administration, especially for pediatric patients[5].

By Application

The cough segment is anticipated to garner a notable share, driven by the rapid escalation of cough cases globally. Other applications include acute and chronic bronchitis, bronchial asthma, and sore throat[1].

By Distribution Channel

Hospitals and retail pharmacies are the primary distribution channels. The hospital segment is expected to hold a significant share due to the trust factor and availability of specialized doctors[1].

By Geography

North America currently holds the largest market share, driven by the strong base of healthcare facilities and rising cases of flu and cold. Asia-Pacific is expected to be the fastest-growing region due to government initiatives, growing healthcare facilities, and a large population pool[3][5].

Price Projections and Market Size

Current Market Size

As of 2024, the dextromethorphan market size was valued at USD 413.78 million. By 2030, the market is expected to reach USD 587.31 million, growing at a CAGR of 4.8% during the forecast period of 2023-2030[2].

Future Projections

The market is projected to exceed USD 724.23 million by 2037, with a CAGR of over 4.4% during the forecast period of 2025-2037. The Asia-Pacific region is expected to witness significant growth, driven by increasing government initiatives and a growing demand for quality healthcare[1].

Key Players

Major players in the dextromethorphan market include AstraZeneca, Aurobindo Pharma, Glenmark Pharmaceuticals Ltd., Pfizer, and Sun Pharmaceutical. These companies are driving innovation and expansion through new product launches and increased research activities[3][5].

Challenges and Restraints

Despite the promising growth prospects, the market faces challenges from side effects associated with dextromethorphan. These side effects can restrain market expansion over the forecast period[3][5].

Regional Insights

North America

This region is expected to witness significant growth due to the high incidence of flu and cold cases, particularly among the geriatric population. The trend towards self-medication and ongoing research into broader applications of dextromethorphan also contribute to market growth[3][5].

Asia-Pacific

Asia-Pacific is anticipated to be the fastest-growing region, driven by government initiatives, growing healthcare facilities, and a large population pool. The availability of massive untapped markets and the growing demand for quality healthcare in this region are key factors[3][5].

Price of Dextromethorphan

The cost of dextromethorphan can vary based on the dosage form and pharmacy. For example, the cost for dextromethorphan oral suspension (30 mg/5 mL) can range from $11.56 to $12.92 for 89 to 148 milliliters, respectively[4].

Illustrative Statistics

  • Cough Cases: Cough is among the most common medical complaints globally, accounting for nearly 30 million clinical visits annually[1].
  • Flu Prevalence: Flu affects around 8.0% of the United States population annually, with a cumulative hospitalization rate of 0.8 per 100,000 people in the 2021 flu season[3].
  • Hospital Growth: The number of hospitals in the United States increased from 5,564 in 2015 to 6,090 in 2019, contributing to the market growth[1].

Expert Insights

"Dextromethorphan is a cornerstone in the management of cough symptoms, especially in the context of respiratory infections like the flu and common cold. The increasing prevalence of these conditions, coupled with advancements in drug formulations, is expected to drive significant growth in the market," says a healthcare analyst.

"The pandemic significantly influenced market dynamics, as heightened anxiety and increased incidence of cough and cold symptoms led to a surge in self-medication, thereby boosting the demand for dextromethorphan."[5]

Key Takeaways

  • The dextromethorphan market is projected to grow significantly, driven by the rising prevalence of respiratory conditions and self-medication practices.
  • North America holds the largest market share, while Asia-Pacific is expected to be the fastest-growing region.
  • The market faces challenges from side effects associated with dextromethorphan.
  • Major players are driving innovation through new product launches and increased research activities.
  • The cost of dextromethorphan varies based on the dosage form and pharmacy.

Frequently Asked Questions (FAQs)

What is the current size of the dextromethorphan market?

The dextromethorphan market was valued at USD 413.78 million in 2024 and is expected to reach USD 587.31 million by 2030[1][2].

Who are the key players in the dextromethorphan market?

Major players include AstraZeneca, Aurobindo Pharma, Glenmark Pharmaceuticals Ltd., Pfizer, and Sun Pharmaceutical[3][5].

Which region is expected to grow the fastest in the dextromethorphan market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period[3][5].

What are the primary drivers of the dextromethorphan market?

The primary drivers include the rising prevalence of respiratory conditions, growing consumer awareness and self-medication practices, and the launch of new formulations[1][2][3].

What are the potential restraints to the dextromethorphan market?

Side effects associated with dextromethorphan are expected to restrain market growth over the forecast period[3][5].

Cited Sources:

  1. Research Nester: Dextromethorphan Market Size, Growth Forecasts 2025-2037
  2. Data Bridge Market Research: Global Dextromethorphan Market – Industry Trends and Forecast to 2030
  3. Mordor Intelligence: Dextromethorphan Market Size & Share Analysis - Growth Trends
  4. Drugs.com: Dextromethorphan Prices, Coupons, Copay Cards & Patient Assistance Programs
  5. Mordor Intelligence: Dextromethorphan Market Size - Table of Contents
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.